“I am incredibly pleased that we are able to make SightScore clinically available in the U.S., marking a significant advancement in the fight against glaucoma,” said Nick Haan, CEO, Seonix Bio.
Request Information
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330